MedTrace Logo

Safety and Efficacy of Oxymetazoline HCl Cream 1.0% in Patients With Persistent Erythema Associated With Rosacea

NCT02132117 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 445

Last updated 2019-11-18

Study results available
· View outcomes & findings →

Summary

This study will evaluate the safety and efficacy of oxymetazoline hydrochloride (HCl) cream 1.0% (AGN-199201) once daily compared to vehicle for the treatment of persistent moderate to severe facial erythema associated with rosacea.

Conditions

  • Erythema
  • Rosacea

Interventions

DRUG

Oxymetazoline HCL Cream 1.0%

Oxymetazoline HCL Cream 1.0% (AGN-199201) applied to the face once daily for 29 days.

DRUG

Vehicle to Oxymetazoline HCL Cream

Vehicle to Oxymetazoline HCL Cream (AGN-199201) applied to the face once daily for 29 days.

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Medical Director · Allergan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2015-04-30
Completion
2015-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02132117 on ClinicalTrials.gov